Centessa Pharmaceuticals plc
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Centessa Pharmaceuticals plc Centessa Pharmaceuticals plc is a clinical-stage biotechnology company that discovers, develops, and delivers transformative medicines addressing unmet medical needs through an asset-centric model integrating specialized programs in neuroscience, hematology, oncology, and other therapeutic areas. The company offers a diversified pipeline of investigational therapies, including ORX750, an orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist in Phase IIa development for narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) to treat excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; ORX142, ORX489, and additional preclinical OX2R agonists targeting neurological, neurodegenerative, and neuropsychiatric disorders; SerpinPC for the treatment of hemophilia A and B; LB101 for solid tumors; MGX292 for pulmonary arterial hypertension (PAH); and early-stage LockBody technology platform assets in immuno-oncology for solid tumors. Founded in 2020 through the merger of 10 private biotech entities backed by Medicxi, Centessa Pharmaceuticals plc maintains dual headquarters in Altrincham, Cheshire, United Kingdom, and Cambridge, Massachusetts, USA, with operations supporting approximately 77 to 180 employees focused on global research, development, and strategic business opportunities across the United States, United Kingdom, and international markets. Recent developments include the announcement in November 2025 of an underwritten public offering of American Depositary Shares (ADSs) to bolster its balance sheet amid ongoing pipeline advancement; Q3 2025 financial results highlighting progress on its potential best-in-class OX2R agonist program; and an amended sales agreement with Leerink Partners LLC enabling up to $250 million in ADS sales, following earlier strategic financing such as the 2021 $300 million facility with Oberland Capital to fund clinical programs and mergers/acquisitions.
Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales
Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
Are CNTA, WSR, GDOT Obtaining Fair Deals for their Shareholders?
Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA
38,432 Shares in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Acquired by B. Metzler seel. Sohn & Co. AG
Here Are Monday’s Top Wall Street Analyst Research Calls: Adobe, Best Buy, Bilibili, Constellation Brands, CoreWeave, Nike, Starbucks, T-Mobile, and More
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders?
Shareholder Alert: The Ademi Firm investigates whether Centessa Pharmaceuticals plc is obtaining a Fair Price for Public Shareholders
Centessa Pharmaceuticals (NASDAQ:CNTA) Reaches New 1-Year High – What’s Next?
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Centessa Pharmaceuticals plc (NASDAQ: CNTA)
LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Boeing, Datadog, Disney, Formula One Group, Nike, Rivian, Rocket Lab, ServiceNow, and More
Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA
Why Centessa Stock Soared Today
Nxera Pharma’s Partner Centessa Pharmaceuticals to be Acquired by Lilly
Options Traders Pick Up Pharma Stock After Eli Lilly Buyout
Eli Lilly stock rises after $7.8B Centessa deal—bet on sleep drugs
Shareholder Alert: The Ademi Firm investigates whether Centessa Pharmaceuticals plc is obtaining a Fair Price for Public Shareholders
Dow Eyes Worst Month Since 2022 Despite Last Minute Flourish
Are APLS, CNTA, BIRD Obtaining Fair Deals for their Shareholders?